Impact of GLP1 Receptor Agonists on Clinical Outcomes in Inflammatory Bowel Disease

Overview

This systematic review and meta-analysis evaluated 11 studies including 16,242 IBD patients treated with GLP1 receptor agonists (GLP1-RAs). GLP1-RAs were associated with significant weight loss and reduced risks of surgery and hospitalizations, particularly in patients with obesity.

Background

Inflammatory bowel disease (IBD), comprising Crohn’s disease and ulcerative colitis, is characterized by chronic gastrointestinal inflammation with complex immune dysregulation. Conventional therapies have limitations including incomplete response and adverse effects. GLP1-RAs, initially developed for type 2 diabetes and obesity, have demonstrated metabolic benefits and potential anti-inflammatory effects relevant to IBD pathophysiology. Obesity in IBD patients is linked to worse clinical outcomes, prompting investigation into GLP1-RAs as a therapeutic option to improve disease course and reduce complications.

Data Highlights

Meta-analysis results for surgery risk: log hazard ratio 0.61 (95% CI: 0.44-0.84, I²=0%), odds ratio 0.46 (95% CI: 0.32-0.67, I²=42%).

Key Findings

• GLP1-RAs induced significant weight loss in IBD patients, with reductions ranging from 9.4 to 11.8 kg after 3 months.
• Use of GLP1-RAs was associated with a lower risk of surgery in IBD patients, supported by consistent hazard and odds ratios.
• Patients with obesity (BMI ≥ 30) experienced greater reductions in hospitalizations and surgical interventions when treated with GLP1-RAs.
• GLP1-RAs may exert anti-inflammatory effects and improve intestinal barrier function, potentially contributing to improved IBD outcomes.
• Weight loss and metabolic improvements from GLP1-RAs may indirectly reduce disease activity and complications in IBD.
• Safety considerations include the risk of intestinal obstruction due to delayed motility, warranting careful monitoring.

Clinical Implications

GLP1-RAs represent a promising adjunctive therapy for IBD patients, especially those with obesity, by promoting weight loss and reducing the need for surgery and hospitalizations. Clinicians should consider the metabolic and potential anti-inflammatory benefits of GLP1-RAs while monitoring for gastrointestinal side effects. Prospective trials are needed to confirm these findings and establish treatment protocols.

Conclusion

GLP1 receptor agonists demonstrate beneficial effects on weight and key clinical outcomes in IBD patients, particularly those with obesity, suggesting a potential role in integrated disease management. Further prospective studies are warranted to validate these results and optimize therapeutic strategies.

References

1. Systematic Review and Meta-Analysis 2025 -- Impact of Glucagon-like Peptide 1 Receptor Agonists on Clinical Outcomes in Inflammatory Bowel Disease